Overview

Dapagliflozin (DAPA) Effects in HFpEF

Status:
Recruiting

Trial end date:
2023-07-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and improve cardiac metabolism.

Phase:

Phase 2

Details

Lead Sponsor:

Mayo Clinic

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin